Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells

详细信息    查看全文

• 作者：S¨ªlvia Cuf¨ª ; Rosa Bonavia ; Alej ; ro Vazquez-Martin ; Bruna Corominas-Faja ; Cristina Oliveras-Ferraros ; Elisabet Cuy¨¤s ; Bego?a Martin-Castillo ; Enrique Barraj¨®n-Catal¨¢n ; Joana Visa ; Antonio Segura-Carretero ; Joaquim Bosch-Barrera ; Jorge Joven ; Vicente Micol ; Javier A. Menendez
• 关键词：Milk thistle ; Silibinin ; Silibinin meglumine ; Lung cancer ; Gefitinib ; EMT
• 刊名：Food and Chemical Toxicology
• 出版年：2013
• 出版时间：October, 2013
• 年：2013
• 卷：60
• 期：Complete
• 页码：360-368
• 全文大小：2076 K

文摘

Silibinin is the primary active constituent of a crude extract (silymarin) from milk thistle plant (Silybum marianum) seeds. We explored the ability of an oral milk thistle extract formulation that was enriched with a water-soluble form of silibinin complexed with the amino-sugar meglumine to inhibit the growth of non-small-cell lung carcinoma (NSCLC) mouse xenografts. As a single agent, oral silibinin meglumine notably decreased the overall volumes of NSCLC tumors as efficiently as did the EGFR tyrosine kinase inhibitor (TKI) gefitinib. Concurrent treatment with silibinin meglumine impeded the regrowth of gefitinib-unresponsive tumors, resulting in drastic tumor growth prevention. Because the epithelial-to-mesenchymal transition (EMT) is required by a multiplicity of mechanisms of resistance to EGFR TKIs, we evaluated the ability of silibinin meglumine to impede the EMT in vitro and in vivo. Silibinin-meglumine efficiently prevented the loss of markers associated with a polarized epithelial phenotype as well as the de novo synthesis of proteins associated with the mesenchymal morphology of transitioning cells. Our current findings with this non-toxic, orally active, and water-soluble silibinin formulation might facilitate the design of clinical trials to test the administration of silibinin meglumine-containing injections, granules, or beverages in combination with EGFR TKIs in patients with EGFR-mutated NSCLC.